Oslo, 23 March 2022: Reference is made to Aker BioMarine ASA's (the "Company") stock exchange announcement on 28 February 2022, regarding the result of the offer under the Employee Share Purchase Program and the related share capital increase.
The share capital increase of NOK 309 882 pertaining to the Employee Share Purchase Program has today, on 23 March 2022, been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). The new registered share capital of the Company is NOK 525 826 398 divided into 87 637 733 shares, each with a par value of NOK 6.00. The new shares are expected to be registered with the Norwegian Central Securities Depository (VPS) later today and will upon such registration be listed on the Oslo Stock Exchange.
For further information please contact:
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
About Aker BioMarine ASA
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.